Clinical Trial Update: A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities [Phase 3]

View source ↗

Summary

Phase 3 study of Aleglitazar for reducing cardiovascular risk in stable cardiovascular disease with Type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Aleglitazar (Aleglitazar)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cardiovascular Disease, Diabetes Mellitus Type 2 | Phase 3 | Status: COMPLETED